Fortin, Elena
Ferrannini, Giulia
Campi, Beatrice
Mellbin, Linda
Norhammar, Anna
Näsman, Per
Saba, Alessandro
Ferrannini, Ele
Rydén, Lars
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 20 June 2022
Accepted: 13 September 2022
First Online: 23 September 2022
Declarations
:
: The PAROKRANK study was approved by the Regional Ethics Committee at Stockholm and was conducted according to the recommendations outlined in the Declaration of Helsinki. All enrolled participants provided their written informed consent.
: All authors have read the paper and agree that it can be published.
: G.F. has received grant support from the Erling-Persson family foundation and reports personal fees from the Swedish Heart and Lung foundation, European Society of Cardiology, Boheringer Ingelheim and Astra Zeneca, but has no conflicts of interest related to this work. LM reports personal fees from Novo Nordisk, Sanofi Aventis, Astra Zeneca, MSD, Boehringer Ingelheim, Novartis and Amgen outside the present work. A.N. has received research grants from the Swedish Heart and Lung foundation, Stockholm County Council, and honorarium from advisory board meetings from Astra Zeneca, Novo Nordisk, MSD Sweden and Boehringer Ingelheim, but has no conflicts of interest related to this work. LR has received research grants from the Swedish Heart and Lung foundation, Stockholm County, Erling-Persson family foundation and Private Foundations, but has no conflicts of interest related to this work. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.